These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20520293)

  • 61. Clinical efficacy of Manasamitra Vataka (an Ayurveda medication) on generalized anxiety disorder with comorbid generalized social phobia: a randomized controlled study.
    Tubaki BR; Chandrashekar CR; Sudhakar D; Prabha TN; Lavekar GS; Kutty BM
    J Altern Complement Med; 2012 Jun; 18(6):612-21. PubMed ID: 22784349
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial.
    Sha Z; Hou Y; Xue C; Li O; Li Z; Wang H; Zhang W; Xu J
    Trials; 2020 Jan; 21(1):107. PubMed ID: 31973702
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder.
    Simen A; Whitlock M; Qiu R; Miceli J; Zumpano L; Du Metz M; Dua P; Binneman B
    J Clin Psychopharmacol; 2019; 39(1):20-27. PubMed ID: 30531477
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interpersonal subtypes and change of interpersonal problems in the treatment of patients with generalized anxiety disorder: a pilot study.
    Salzer S; Pincus AL; Winkelbach C; Leichsenring F; Leibing E
    Psychotherapy (Chic); 2011 Sep; 48(3):304-10. PubMed ID: 21604899
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Influence of Simvastatin as Augmentative Therapy in the Treatment of Generalized Anxiety Disorder: A Pilot Randomized, Placebo-Controlled Study.
    Mirzaei E; Mirjalili M; Jahangard L; Haghighi M; Yasrebifar F; Mohammadi Y; Larki-Harchagani A; Mehrpooya M
    Neuropsychobiology; 2021; 80(3):242-252. PubMed ID: 33070132
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder.
    Michelson D; Hargreaves R; Alexander R; Ceesay P; Hietala J; Lines C; Reines S
    Int J Neuropsychopharmacol; 2013 Feb; 16(1):1-11. PubMed ID: 22433185
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review.
    Samuel M; Zimovetz EA; Gabriel Z; Beard SM
    Int Clin Psychopharmacol; 2011 Mar; 26(2):63-8. PubMed ID: 21088608
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ziprasidone decreases cortisol excretion in healthy subjects.
    Meier A; Neumann AC; Jordan W; Huether G; Rodenbeck A; Rüther E; Cohrs S
    Br J Clin Pharmacol; 2005 Sep; 60(3):330-6. PubMed ID: 16120074
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of vortioxetine in working patients with generalized anxiety disorder.
    Christensen MC; Loft H; Florea I; McIntyre RS
    CNS Spectr; 2019 Apr; 24(2):249-257. PubMed ID: 29081307
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorder.
    Lalovic B; Hutmacher M; Frame B; Miller R
    J Clin Pharmacol; 2011 May; 51(5):706-18. PubMed ID: 20663989
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Individualized Homeopathic Medicines in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial.
    Parewa M; Burman AS; Brahma A; Rutten L; Sadhukhan S; Misra P; Gupta B; Saklani N; Michael J; Basu A; Ali SS; Koley M; Saha S
    Complement Med Res; 2021; 28(5):407-418. PubMed ID: 33662951
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Explanatory attributions of anxiety and recovery in a study of kava.
    Abraham KC; Connor KM; Davidson JR
    J Altern Complement Med; 2004 Jun; 10(3):556-9. PubMed ID: 15253862
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder.
    Frame B; Miller R; Hutmacher MM
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):565-84. PubMed ID: 19904583
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sleep architecture in ziprasidone-treated bipolar depression: a pilot study.
    Baskaran A; Summers D; Willing SL; Jokic R; Milev R
    Ther Adv Psychopharmacol; 2013 Jun; 3(3):139-49. PubMed ID: 24167686
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A comparison of a β2-adrenoceptor antagonist (ICI 118,551), diazepam and placebo in the treatment of acute anxiety.
    Cooper SJ; Gilliland A; Kelly C; McGilloway S
    J Psychopharmacol; 1991 Jan; 5(2):155-9. PubMed ID: 22282368
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Failed efficacy of ziprasidone in the treatment of post-traumatic stress disorder.
    Ramaswamy S; Driscoll D; Smith LM; Bhatia SC; Petty F
    Contemp Clin Trials Commun; 2016 Apr; 2():1-5. PubMed ID: 29736440
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder.
    McDougle CJ; Thom RP; Ravichandran CT; Palumbo ML; Politte LC; Mullett JE; Keary CJ; Erickson CA; Stigler KA; Mathieu-Frasier L; Posey DJ
    Neuropsychopharmacology; 2022 May; 47(6):1263-1270. PubMed ID: 35241779
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam.
    Akhondzadeh S; Naghavi HR; Vazirian M; Shayeganpour A; Rashidi H; Khani M
    J Clin Pharm Ther; 2001 Oct; 26(5):363-7. PubMed ID: 11679026
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set.
    Kasper S; Möller HJ; Volz HP; Schläfke S; Dienel A
    Int Clin Psychopharmacol; 2017 Jul; 32(4):195-204. PubMed ID: 28379882
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A placebo-controlled study of Kava kava in generalized anxiety disorder.
    Connor KM; Davidson JR
    Int Clin Psychopharmacol; 2002 Jul; 17(4):185-8. PubMed ID: 12131602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.